IDYA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the investor's long-term strategy, beginner knowledge level, and available investment capital, IDEAYA Biosciences Inc (IDYA) presents a good buying opportunity. The stock has strong upcoming catalysts, favorable analyst ratings, and a positive long-term growth outlook, making it suitable for a patient, long-term investor.
The technical indicators are neutral overall. The MACD is below zero but negatively contracting, the RSI is neutral at 46.339, and moving averages are converging. The stock is trading near its pivot point of 32.494, with key resistance at 34.669 and support at 30.318. No clear bullish or bearish signals are present.
Citi's 'upside 90-day catalyst watch' with a $65 price target and favorable setup into Phase 2/3 OptimUM-02 trial data expected in late March.
Multiple analysts have raised price targets recently, with strong confidence in upcoming trial results.
IDEAYA's Phase 2/3 trial data for metastatic uveal melanoma will be presented in May, which could act as a significant catalyst.
Revenue growth of 55.37% YoY in the latest quarter.
Net income dropped significantly by -36.10% YoY, and EPS fell by -36.91% YoY, reflecting ongoing financial losses.
The MACD and RSI do not indicate strong momentum, and technical indicators are neutral.
In Q4 2025, IDEAYA reported a 55.37% YoY increase in revenue to $10.88M, showcasing strong top-line growth. However, net income dropped by -36.10% YoY to -$83.27M, and EPS declined by -36.91% to -0.94, reflecting ongoing operational losses. Gross margin remained strong at 100%.
Analysts are overwhelmingly positive on IDYA, with multiple Buy ratings and price targets ranging from $45 to $65. Citi and Wedbush highlight the strong potential of the upcoming Phase 2/3 OptimUM-02 trial data, with a high probability of success and significant upside potential.
